PE-22-28 — Deep Research (Cognitive & Nootropic)

Published · Researched 2026-09-21

Research file written 2026-09-21. Social-first methodology: community sources weighted before vendor pages.

1. Overview

PE-22-28 is a seven-amino-acid peptide fragment (not a 28-mer — the name refers to residues 22–28 of the parent propeptide): sequence GVSWGLR, molecular formula C₃₅H₅₅N₁₁O₉, molecular weight 773.88 g/mol, CAS 1801959-12-5 (TargetMol catalog T76311; bioscience.co.uk datasheet). It is derived from the sortilin-related propeptide / spadin system and was designed as a more stable TREK-1 potassium-channel inhibitor — laboratory testing found it inhibits human TREK-1 with an IC₅₀ of ~0.12 nM, substantially stronger than the parent spadin peptide in the same system (PureRawz research summary, citing the primary work).

Preclinical work reports TREK-1 inhibition, rodent antidepressant-like behavior, neurogenesis/synaptogenesis markers, and longer action than spadin. It fits the mood/antidepressant frontier better than a conventional cognitive enhancer — it is in this category because the community discusses it alongside the nootropic peptides and vendors list it in the neuro section, not because human cognitive-enhancement data exists. No controlled human validation was found.

2. Social standing

The social-pulse addition to this category: chosen because it has emerging community/vendor discussion around the spadin/TREK-1 mechanism while still being essentially unvalidated in humans.

• YouTube: a 2026 self-experiment video described mood/mental-energy effects and cycling — one creator's account, not evidence.
• Vendor research pages (PureRawz, Core Peptides, Biotech Peptides, CityPeopleOnline): the most detailed public explainers — antidepressant research, neurogenesis research, TREK-1 affinity (0.12 nM IC₅₀). Proves the mechanism story is well-articulated commercially; proves nothing about human effects.
• ResearchGate figure (spadin analog sequences): the primary-literature anchor for the GVSWGLR sequence identity.
• Prescription-channel listing (Natural Med Doc): lists PE-22-28 at $285 as a physician-gated "peptide therapy" — proves at least one clinic is willing to sell the TREK-1 story at a premium; the marketing claims (rapid depression management, "fewer side effects than antidepressants") are UNVERIFIED in humans and should be read as sales copy.
• Threads / Facebook Groups: no PE-22-28-specific owner content surfaced this round.
• Recurring community position: curiosity without validation — "interesting mechanism, no human data."
• Overhyped warnings: any claim of human antidepressant efficacy, neurogenesis in humans, or safety vs. conventional antidepressants is UNVERIFIED — all data is preclinical.

3. Social validation — Tier 3 / UNVALIDATED — included for comparison, low community signal

• YouTube 2026 self-experiment video: proves at least one self-experimenter documented mood/mental-energy effects and cycling. Proves minimal real-world use — a single anecdote.
• Vendor research pages (PureRawz, Core Peptides, Biotech Peptides): prove the TREK-1/spadin mechanism story is consistently told across vendors with the same numbers (0.12 nM IC₅₀, 7-aa, GVSWGLR). Proves commercial narrative consistency, not community endorsement.
• ResearchGate primary-literature figure: proves the sequence identity (GVSWGLR) is anchored in published spadin-analog work. Proves identity, not efficacy.
• June-2026 GitHub hukus/llimitless scan: flags PE-22-28 as an emerging-curiosity node — vendor repetition, no human validation found. Proves the scan's authors see the same pattern: noise without signal.
• Missing: no named Facebook Group posts, no Threads owner content, no Instagram owner content, no forum experience threads, no independent reviews found this round.

4. Key specs table

5. Pricing (observed 2026-09-21)

Marketplace used range: not observed — report honestly, no used-market data found. Street range clusters $38–72 per 8–10 mg — accessible frontier pricing; the prescription-channel $285 listing and the $693/mg lab-grade reference are not street prices and are shown for context only.

6. What's included / what's needed

• Lyophilized vial ships as powder; reconstitution solution typically sold separately.
• No reconstitution or dosing protocol exists in any research literature; all use protocols are community folklore. The YouTube self-experimenter's cycling protocol is one person's account, not guidance.

7. Support reality

• COA culture: Amino USA and Alpha Omega advertise batch/lot third-party testing with COA archives; this is the better end of the frontier market.
• Prescription-channel red flag: the Natural Med Doc $285 physician-gated listing makes human therapeutic claims (depression management, neurogenesis, "fewer side effects than antidepressants") with no human data behind them — premium pricing on an UNVALIDATED story.
• Gray-market risk: research-use-only labeling everywhere else; no pharmacy QA chain.

8. Community verdict

PE-22-28 is the category's purest "mechanism story" stock: a crisp, well-documented preclinical rationale (TREK-1 inhibition at 0.12 nM, spadin lineage, rodent antidepressant behavior) with essentially no human community behind it yet. It earned its place in this track on social-pulse grounds — vendors and creators are talking about it — but the honest verdict is curiosity, not confidence. It belongs on a watchlist, not in a stack.

9. Regulatory & safety status

• USA/EU: not FDA or EMA approved; sold as a research chemical not for human use. No controlled human trials; no human safety data.
• Community-reported side effects: none documented in this session's extraction (essentially no review footprint).

Images

5/8 views present in img/: pe-22-28-hero.jpg, pe-22-28-side.jpg, pe-22-28-rear.jpg, pe-22-28-top.jpg, pe-22-28-in-use.jpg (owner/in-use format photo). All verified valid JPEGs. Missing views: detail, scale, box/accessories — no distinct real photos found for these views; named honestly.

Not medical advice. This is community research, not a recommendation. PE-22-28 is an unapproved research chemical with no human safety data; it is not for human use. Talk to a clinician before considering any peptide.

Named sources

• TargetMol — Sequence: GVSWGLR (7 amino acids; residues 22–28 of the spadin propeptide system)
• ResearchGate primary figure — Sequence: GVSWGLR (7 amino acids; residues 22–28 of the spadin propeptide system)
• bioscience.co.uk datasheet — Molecular formula: C₃₅H₅₅N₁₁O₉
• bioscience.co.uk — Molecular weight: 773.88 g/mol
• TargetMol catalog T76311 — CAS: 1801959-12-5
• YouTube — a 2026 self-experiment video described mood/mental-energy effects and cycling — one creator's account, not evidence. (2026)
• YouTube 2026 self-experiment video — proves at least one self-experimenter documented mood/mental-energy effects and cycling. (2026)

Source URLs were not recorded for these references.